Metformin in obesity, cancer and aging: addressing controversies
about
Biomarkers of cancer angioprevention for clinical studiesThe search for antiaging interventions: from elixirs to fasting regimensEntitymetrics: measuring the impact of entitiesFrom rapalogs to anti-aging formula.Metformin limits the adipocyte tumor-promoting effect on ovarian cancer.TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists.Selective anti-cancer agents as anti-aging drugsEnergy restriction and potential energy restriction mimetics.Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signalingMetformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosisSignaling pathway activation drift during aging: Hutchinson-Gilford Progeria Syndrome fibroblasts are comparable to normal middle-age and old-age cellsComparison of rapamycin schedules in mice on high-fat diet.Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cellsWhen Anti-Aging Studies Meet Cancer Chemoprevention: Can Anti-Aging Agent Kill Two Birds with One Blow?Metformin for cancer and aging prevention: is it a time to make the long story short?NF-κB pathway activators as potential ageing biomarkers: targets for new therapeutic strategies.One-carbon metabolism: an aging-cancer crossroad for the gerosuppressant metforminM(o)TOR of aging: MTOR as a universal molecular hypothalamusMetformin blocks progression of obesity-activated thyroid cancer in a mouse model.Contrasting effects of chronic, systemic treatment with mTOR inhibitors rapamycin and metformin on adult neural progenitors in mice.Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer.Dysregulation of the mTOR pathway in p53-deficient mice.FoxO1 controls lysosomal acid lipase in adipocytes: implication of lipophagy during nutrient restriction and metformin treatment.Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance.Concentration-dependent metabolic effects of metformin in healthy and Fanconi anemia lymphoblast cells.Metformin: A Hopeful Promise in Aging Research.Metformin Treatment Prevents Sedentariness Related Damages in Mice.The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells.Potential and real 'antineoplastic' and metabolic effect of metformin in diabetic and nondiabetic postmenopausal females.Immunosuppressants in cancer prevention and therapyCancer endocrinology through own experience: areas for further thought and development. Interview by Natasha Galukande.Pharmabiotics as an Emerging Medication for Metabolic Syndrome and Its Related Diseases.A pharmacist's perspective on metformin use and cancer outcomes.
P2860
Q26774580-C86D931E-441A-4C8D-9DE1-8EFA107B2537Q26863497-9BFA1999-4CE6-4D04-8C3F-3CB8A76E1DDFQ28535985-F2025AA5-F11D-4C86-980E-05288401BA06Q33829205-57047E0A-9B1D-411E-9EEC-74E17265BD72Q34104019-D245CE73-2B15-4D9A-8693-3AB790966D36Q34391710-78BD8271-7D97-4723-AED0-281DE93C947CQ34392470-3AB2E2F2-DF75-463C-BB66-8F45BCC0F827Q34495145-E171E5C6-DE9E-421D-AA57-8E7CD485ACB4Q34567724-105FDCBF-C4BE-4CDD-9363-9D5854BC0812Q35114963-08919C3D-D863-4ACD-BC42-7DF0B539C16DQ35149536-C9EE9C13-5C67-47B9-B411-93DFFF5C1309Q36189078-830ABFC0-B761-4F97-9B62-EF0F6BC12B84Q36428086-83BD9AFA-27FC-4AF5-ADC5-9B826467B3E9Q36442945-EE3C7104-29DA-4BC1-8F79-704458245718Q36545393-D7D7F9CC-2FA1-4976-A049-5825ACBE5816Q36964401-517A38DD-B074-4BBC-89A3-E4471AD36767Q37001540-8D5FD9B6-7320-4A60-BA6F-ADC9135B9696Q37152775-746C1BB8-F6F0-40E5-840E-53B091AD9613Q37376404-72D30AE0-0345-4535-A136-860A29DD8A4BQ37470910-E0CC4611-85FF-42DD-BD77-CEB0C4E35DE9Q37521408-F94789D8-B4DF-4D9E-8F95-AD2ADF88DA7EQ37548879-C38C8665-8C07-40D5-8917-F5DBFA9D18ADQ37577484-9EF204E7-3F11-406B-915E-D2B6B46CE8CCQ37606430-5E6A385C-6CDF-4F2D-BD76-F8B3DA2DF767Q38691486-23D38F89-3D99-4D91-9C66-D664D0580F97Q38756907-206BA132-DDDB-4785-A046-E6A9A85BC667Q38809599-EFBD4EA6-2A97-4BD0-8D92-4D1792FA478FQ38959006-044800C6-17C9-487F-8156-60C052747C98Q39030844-3E2999F9-3085-4BAE-A6B3-FE00AD563AB4Q42505783-AF2BF8A8-F8EE-45BE-BA38-805C287E18A3Q48210184-49256369-BA97-41F9-9325-19A9199AD369Q50075636-07CE3929-3D41-4849-A629-78C4E10C818DQ53233111-B020C4D9-BE47-492E-90FA-55810BD8D9F9
P2860
Metformin in obesity, cancer and aging: addressing controversies
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Metformin in obesity, cancer and aging: addressing controversies
@ast
Metformin in obesity, cancer and aging: addressing controversies
@en
Metformin in obesity, cancer and aging: addressing controversies
@nl
type
label
Metformin in obesity, cancer and aging: addressing controversies
@ast
Metformin in obesity, cancer and aging: addressing controversies
@en
Metformin in obesity, cancer and aging: addressing controversies
@nl
prefLabel
Metformin in obesity, cancer and aging: addressing controversies
@ast
Metformin in obesity, cancer and aging: addressing controversies
@en
Metformin in obesity, cancer and aging: addressing controversies
@nl
P2860
P921
P3181
P356
P1433
P1476
Metformin in obesity, cancer and aging: addressing controversies
@en
P2093
Lev M Berstein
P2860
P3181
P356
10.18632/AGING.100455
P407
P5008
P577
2012-05-01T00:00:00Z